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Abstract
Background:  The prognosis for metastatic melanoma remains poor even with traditional
decarbazine or interferon therapy. 5-year survival is markedly higher amongst patients undergoing
metastatectomy. Unfortunately not all are suitable for metastatectomy. Alternative agents for
systemic therapy have, to date, offered no greater rates of survival beyond traditional therapy. A
toll-like receptor 9 agonist, PF-3512676 (formerly known as CPG 7909) is currently being evaluated
for its potential.
Case presentation: We present the case of a 54-year-old Caucasian male with completely
resected metastatic cutaneous melanoma after immunotherapy. The patient initially progressed
during adjuvant high-dose interferon, with metastases to the liver, spleen, and pelvic lymph nodes.
During an 18-month treatment period with PF-3512676 (formerly known as CPG 7909), a
synthetic cytosine-phosphorothioate-guanine rich oligodeoxynucleotide, slow radiologic disease
progression was demonstrated at the original disease sites. Subsequent excision of splenic and
pelvic nodal metastases was performed, followed by resection of the liver metastases. Histologic
examination of both hepatic and splenic melanoma metastases showed extensive necrosis.
Subsequent disease-free status was demonstrated by serial positron emission tomography (PET).
Conclusion: Existing evidence from phase I/II trials suggests systemic treatment with PF-3512676
is capable of provoking a strong tumor-specific immune response and may account for the
prolonged tumor control in this instance.
Background
Metastasis is by far the most common cause of death in
patients with malignant melanoma, with estimated rates
of cutaneous malignant melanoma metastasis of approxi-
mately 14% [1]. Furthermore, only about 7% of meta-
static melanoma cases are suitable for metastasectomy. In
general, less than 6% of patients with metastatic disease
survive up to 5 years, but in those undergoing complete
resection, survival approaches 25% at 5 years [2,3]. In
patients unsuitable for surgical intervention, systemic
therapy with dacarbazine remains the standard of care
with few long-term survivors and a median survival of
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only 6 months [4]. A number of novel agents are currently
undergoing evaluation with the hope of improving out-
comes beyond traditional therapy [5,6]. The case report
we present describes unique radiological and histopatho-
logical responses to one particular new agent: PF-
3512676.
Case presentation
A 54-year-old Caucasian male presented with a 1.5 mm
Breslow malignant melanoma on his left shin in February
2002 and was managed with wide local excision. At 16
months follow-up, recurrence in the left inguinal lymph
nodes was detected. The patient underwent groin dissec-
tion, and all 8 lymph nodes showed either partial or com-
plete replacement by metastatic melanoma on histology
Computed tomography (CT) of the abdomen and pelvis Figure 1
Computed tomography (CT) of the abdomen and pelvis. CT scanning immediately before initial pelvic tumor debulking 
at 46 months after presentation shows A). Large splenic metastasis (100.3 mm), B). Metastasis to the left iliac vein lymph nodes 
(41.3 mm), and C). A slightly lower view of the splenic metastasis showing the 2 liver lesions. D). CT of the abdomen, post-
splenectomy and pelvic tumor debulking, and pre-liver resection (2 liver metastases 20 mm and 15 mm in segments V and VI) 
at 51 months.World Journal of Surgical Oncology 2008, 6:30 http://www.wjso.com/content/6/1/30
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with extracapsular extension. No necrosis was seen in
either the skin or the lymph node specimens at this stage.
Surgery was followed by adjuvant high-dose interferon-
α2a therapy, consisting of 1 month of intravenous inter-
feron 5 days a week followed by 11 months of subcutane-
ous lower-dose interferon 3 days a week. Progression was
documented at 6 months by computed tomography (CT),
which confirmed a large metastasis in the spleen, left iliac
lymphadenopathy, and 2metastases in the liver (Figure
1).
The patient enrolled into a randomized phase II clinical
trial in which he was treated with the toll-like receptor 9
agonist PF-3512676 (formerly known as CPG 7909), a
synthetic cytosine-phosphorothioate-guanine rich oligo-
deoxynucleotide. PF-3512676 induces activation of plas-
macytoid dendritic cells and enhances cell surface
expression of costimulatory molecules (eg, B7) and is
hypothesized to promote an antitumor immune response
by enhancing antigen presentation to T cells and promot-
ing proliferation of antigen-specific cytotoxic T lym-
phocytes. CT scanning was performed during the study
initially 6 weekly for 6 months, then at 8 weekly intervals.
The patient achieved stable disease over a 20-month
period. Thereafter, disease progression, according to
RECIST radiological parameters [7], was documented at
all disease sites. It is worth noting that during the therapy
period, the patient experienced grade 1cutaneous reaction
(minor erythema) at the site of the excised primary lesion,
the left shin. Figure 1A–C shows the 100.3 mm splenic
metastasis (Figure 1A), the 41.3 mm pelvic metastases
along the left iliac vein lymph node chain (Figure 1B), and
the 2 metastatic liver lesions (Figure 1C and 1D) shortly
after completion of the PF-3512676 treatment period. In
view of the indolent disease biology and the absence of
new metastatic lesions during treatment, tumor metasta-
sectomy was undertaken. Initial left iliac lymphadenec-
tomy and splenectomy was followed by adjuvant pelvic
radiotherapy. During a second procedure, the patient
underwent staging laparoscopy followed by liver resection
of segments V and VI with cholecystectomy. Surgical clear-
ance was confirmed by whole body PET scanning at 1
month and 6 months after liver resection, indicating no
disease activity. Following up imaging is currently being
performed with 3 monthly alternating CT and PET scan-
ning.
Histology findings
Macroscopic examination of the liver lesions revealed a
dark brown nodule (25 × 20 × 15 mm) comprised of 2
adjoining lesions reaching the liver capsule but remaining
clear of the resection margin. Sections throughout the
specimen revealed an almost entirely necrotic nodule
with a well-demarcated fibrous capsule (Figure 2). Many
of the cells within the inner margin of the capsule con-
tained a granular brown pigment showing no reaction in
Perl's preparation. However, because of loss of color when
placed in a melanin bleach preparation, the pigment was
identified as melanin. The majority of these pigmented
cells tested positive for CD68, indicating that they were
macrophages. In contrast, a very few number of cells
tested positive for S100, indicating that these cells were
melanoma. Hence, the vast majority of these pigmented
cells were macrophages, with only a small number identi-
fied as melanoma cells.
The spleen specimen also showed a similar histologic pat-
tern, with almost the entire parenchyma replaced by fria-
ble necrotic tissue. Moreover, sections contained large
areas of necrosis with admixed melanoma cells. In addi-
tion, the left iliac specimen was largely hemorrhagic with
blood clots, fibroadipose tissue, and deposits of viable
malignant melanoma.
Discussion
This case report illustrates the potential role for metasta-
sectomy in selected cases of metastatic melanoma, despite
multiple disease sites. The history of this patient followed
a remarkably indolent course on PF-3512676 therapy,
even with early recurrence on high-dose interferon.
Although progressive disease was documented according
to RECIST criteria, there was in fact minor enlargement of
the known disease over a number of months. The pathol-
ogy suggests an inflammatory response to account for the
latter, but it remains unclear whether the history was a
consequence of indolent biology or therapy.
Malignant melanoma is known to be 1 of 3 types of malig-
nancies with a particular tendency to spontaneously
regress. The other 2 types of malignancies are neuroblast-
oma and renal cell carcinoma [8]. Malignant melanoma
accounts for 11% of all reported cases of spontaneous
cancer regression but only contributes 1.8% of the total
incidence of all types of cancer. However, most of these
regressions are partial and rarely occur in metastatic cases
(0.22% to 0.27% of all malignant melanoma cases) [8-
13]. Regression of visceral metastatic melanoma com-
pared with local cutaneous, subcutaneous, and lymph
node spread is exceptionally rare [11-13]. In addition,
spontaneous regression of visceral melanoma metastases
appears to be short-lived, with only 1 case in the literature
demonstrating long-term regression [14]. The observa-
tions in this patient suggest that immunotherapy with PF-
3512676 may have contributed to the necrosis of meta-
static lesions.
The traditional approach to metastatic melanoma
remains systemic therapy, with no consistent survival
advantage reported with multiagent therapy. Immune
therapy-based treatment may induce more durable remis-World Journal of Surgical Oncology 2008, 6:30 http://www.wjso.com/content/6/1/30
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sions than standard chemotherapy in highly selected
patients; however, a survival advantage has not been con-
firmed from randomized clinical trials [15]. Even the
more recent, experimental agents (IL-2, IL-12, Granulo-
cyte Macrophage-Colony Stimulating Factor and antigen
vaccines as well as agents aimed at inhibiting oncogene
activity) have showed no clinical benefit over decarbazine
in Phase III trials in terms of progression-free survival
[16,17]. Success of immunotherapy has been limited by
the difficult challenge of provoking an adequate immune
response while limiting toxicity. The more recent
approaches, aimed at directing the immune response to
the tumor cells alone, involve using tumor antigens to
produce vaccines. This approach has been applied to Bcell
lymphomas and melanomas. However, many vaccines
have been proven to be poorly immunogenic and this
appears to be due, in part at least, to the immune-damp-
ening effect of the tumor environment. Certain factors
have been found to inhibit (e.g. Tregs) or prevent the mat-
uration of an adequate anti-tumor immune response [17].
As such, the search for suitable vaccine adjuvants has been
ongoing.
In this case study, a toll-like receptor 9 agonist (PF-
3512676) composed of cytosine-phosphorothioate-gua-
nine (CpG)-rich oligodeoxynucleotides was the treatment
used. These nucleotides act analogously to bacterial DNA
by directly activating plasmacytoid dendritic cells and
plasma cells and inducing both T- and B-cell responses as
well as cytokine (e.g. interferon-α) production [18,19].
Photomicrograph of liver metastases Figure 2
Photomicrograph of liver metastases. A). Liver metastasis showing almost complete necrosis within a fibrous capsule. 
Cells adjacent to the capsule contain a brown pigment. B). The pigment disappears in melanin bleach preparation. C). Very few 
cells stained positive for S100. In this section, only 1 positive cell was observed, staining a homogeneous dark brown color 
compared with the dotted granular brown appearance of neighboring cells. D). The majority of the pericapsular cells containing 
melanin stained positive for CD68, indicating that they are macrophages.World Journal of Surgical Oncology 2008, 6:30 http://www.wjso.com/content/6/1/30
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These CpG-rich oligodeoxynucleotides have exhibited evi-
dence of augmenting immune responses to both tumor
vaccines and interferon [15] and are currently being eval-
uated in clinical trials in refractory/relapsing breast can-
cer, advanced small cell lung cancer, and melanoma [19].
A recent phase I trial, in 8 patients with advanced
melanoma, of PF-3512676 with melanoma antigen
(Melan A26) compared levels of melanoma-specific cyto-
toxic T-cells generated by the PF-3512676 vaccine with
another vaccine that had demonstrated some success in
mice but minimal effect in humans [18]. The PF-3512676
vaccine generated a 43-fold increase in melanoma-specific
T-cells compared with prevaccination. This increase was
23 times the level observed with the other vaccine.
Reported side effects experienced by the majority of
patients included transient malaise, nausea, myalgia,
arthralgia, headaches, and fatigue. All patients also experi-
enced inflammation at the injection site on each vaccina-
tion. In another study, the combination of interferon α
and CpG oligodeoxynucleotides was shown to have addi-
tive antitumor activity in murine models of melanoma
[20]. Results indicated that CpG oligodeoxynucleotides
appeared to greatly enhance tumor infiltration compared
with interferon.
Another placebo-controlled Phase II trial looked at the
effect of PF3512676 on the immunological response at
the sentinel lymph node in patients with early stage
melanoma. Results showed a significant increase in the
number of mature dendritic cells capable of stimulating T-
cells and a reduction in Treg immunosuppression [21].
Most of the phase II trials to date have been directed more
at investigating the effects of PF-3512676 on the host
immune system and less on actual clinical outcomes of
patients, in a bid to first elicit the molecular and cellular
mechanisms of action to provide a biological basis for its
use in humans. However one recent phase II trial of sin-
gle-agent PF-3512676 for 24 weeks in patients (N = 20)
with metastatic melanoma was performed with an analy-
sis of clinical response as measured by the RECIST param-
eters [22]. Two patients experienced a partial response,
and three patients had stable disease for 8 weeks, and then
progressed. The remainder progressed throughout the
trial. Responses were observed in lung, skin, and soft tis-
sue. Treatment duration and follow up was much shorter
than that performed in our patient. Patient numbers were
also small.
Conclusion
The case we present here appears to be the only such case
in the literature reporting evidence of necrosis of extensive
visceral metastases in response to this new form of immu-
notherapy. The data above suggest that PF-3512676 is
capable of inducing a strong tumor antigen-specific T-cell
response when used with tumor vaccines and can induce
marked necrosis in melanoma metastases when used as a
single agent. An ongoing phaseI/II clinical trial using 2
different doses of PF-3512676 has indicated no dose-
related differences in side effect profiles to date. However,
the balance between tumor response and toxicity requires
further attention [23]. The majority of research on CpG
oligodeoxynucleotides to date has focused on eliciting cel-
lular mechanisms in animal models. Results from current
and new clinical trials in humans are awaited to evaluate
clinical responses.
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